Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Findings from the SCRUM Japan Genie screening projectin breast cancer

Hiroji Iwata • 16 May 2024
ESMO Breast 2024
Breast Cancer Abemaciclib

Hiroji Iwata, MD, PhD, Nagoya City University, Nagoya, Japan, details findings from the SCRUM Japan GENIE screening project focused on breast cancer. The project involves screening tissue and blood samples before and after treatment with CDK4/6 inhibitors like abemaciclib. Recent data highlight the presence of gene alterations, including PIK3CA mutations and RB1 expression changes. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hiroji Iwata

Emerging mechanisms of resistance to endocrine therapies in HR+ breast cancer
1:00
Emerging mechanisms of resistance to endocrine therapies in HR+ breast cancer
Hiroji Iwata • 16 May 2024
NEOS: prognosis of ER+ breast cancer pts who received neoadjuvant ET with/without adjuvant chemo
5:34
NEOS: prognosis of ER+ breast cancer pts who received neoadjuvant ET with/without adjuvant chemo
Hiroji Iwata • 3 Dec 2021
Use of neoadjuvant approaches in breast cancer during the COVID-19 pandemic
2:35
Use of neoadjuvant approaches in breast cancer during the COVID-19 pandemic
Hiroji Iwata • 3 Dec 2021
Future research directions for ER+ positive breast cancer
1:31
Future research directions for ER+ positive breast cancer
Hiroji Iwata • 3 Dec 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals